NOVEMBER 6, 2014 DCVAX-DIRECT ABSTRACT (POTENTIAL "SYSTEMIC" EFFECTS) that was submitted approximately July 8, 2014. :) The Poster presentation tomorrow should bring us more current results.
Activated autologous dendritic cells injected intratumorally are able to overcome local and systemic immune suppression imposed by the tumor and its microenvironment Vivek Subbiah1*, Omar Kayaleh2, Ravi Murthy3, David Hong3, Siqing Fu3, Aung Naing3, Anthony Conley3, Chitra Hosing3, Indreshpal Kaur3, Robert Prins4, Funda Meric-Bernstam3 and Marnix Bosch5
* Corresponding author: Vivek Subbiah
Author Affiliations 1 Department of Investigational Cancer Therapeutics, University of Texas M.D. Anderson Cancer Center Houston, TX, USA
2 Orlando Health, FL, USA
3 University of Texas M.D. Anderson Cancer Center Houston, TX, USA
4 ULCA, Los Angeles, CA, USA
5 Northwest Biotherapeutics, USA
For all author emails, please log on.
Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P61 doi:10.1186/2051-1426-2-S3-P61
The electronic version of this article is the complete one and can be found online at: www.immunotherapyofcancer.org/content/2/S3/P61
Published: 6 November 2014
Introduction Cancer vaccines aiming to induce anti-tumor immune responses are generally considered most effective in an environment with minimal residual disease, due to the immunosuppressive effects exerted by most cancers. We hypothesized that appropriately activated autologous dendritic cells (DCVax®-Direct) may be able to overcome this suppressive environment through the production of inflammatory cytokines and through the activation of signal transduction pathways that condition the dendritic cells for completion of the maturation processes even after intratumoral injection.
Methods A Phase I trial that enrolled 36 patients with diverse solid tumor cancers. Three intratumoral DCVax-Direct injections were given at Day 0, 7 and 14, followed by additional injections at weeks 8, 16 and 32. Patients were followed for safety parameters, for tumor response using appropriate imaging, and for pathological evaluation of tumor tissue from serial biopsies. Evaluation of circulating immune cell populations as well as circulating cytokines is in progress.
Results Recurrent low to moderate fevers were seen in most patients following DCVax-Direct administration. Substantial apparent increases in tumor size, were observed on CT or PET scans in the majority of patients. Tumor biopsies of injected lesions demonstrated extensive tumor necrosis, as well as large immune cell accumulations, containing CD4+ and CD8+ T cells and other immune cells. In addition, these biopsies often showed paucity of tumor cells or, in some cases, no tumor cells were detected in the biopsies. In the one patient assessed to date for circulating immune cells, a normalization of the CD4:CD8 ratio was seen. Analysis of longer-term imaging data to assess tumor response is in progress.
Conclusions Intratumoral injection of activated, autologous dendritic cells is safe and feasible. The accumulation of immune cells in tumor biopsies suggests that these injections have the potential to successfully change the tumor microenvironment from immunosuppressive to one that is conducive to the induction of anti-tumor immune responses. Normalization of the CD4:CD8 T cell ratio in circulation demonstrates the potential for SYSTEMIC EFFECTS of this novel therapeutic approach.
ClinicalTrials.gov Identifier: NCT01882946
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
AI
